At the light of previous findings regarding the relevance of WNT6 promoting resistance to chemotherapy (Gonçalves et al., 2018), it will also be interesting to understand whether WNT6 may be a clinically useful biomarker predictive of therapy response, similarly to what has been done for MGMT promoter methylation status within IDHwt gliomas, in which patients whose tumors lack MGMT promoter methylation are treated with radiotherapy only (Louis et al., 2016). The gene discussed is MGMT; the disease is central nervous system cancer.